|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-3-1
|
|
pubmed:abstractText |
Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is a novel antitumor agent currently undergoing clinical trials in hormone-refractory prostate cancer. This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0270-4137
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
22-32
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:14991863-Animals,
pubmed-meshheading:14991863-Antineoplastic Agents, Alkylating,
pubmed-meshheading:14991863-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14991863-Cell Line, Tumor,
pubmed-meshheading:14991863-Drug Synergism,
pubmed-meshheading:14991863-Humans,
pubmed-meshheading:14991863-Male,
pubmed-meshheading:14991863-Mice,
pubmed-meshheading:14991863-Mice, Nude,
pubmed-meshheading:14991863-Mitoxantrone,
pubmed-meshheading:14991863-Prostatic Neoplasms,
pubmed-meshheading:14991863-Sesquiterpenes,
pubmed-meshheading:14991863-Taxoids,
pubmed-meshheading:14991863-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
|
|
pubmed:affiliation |
Research and Development Department, MGI Pharma, Inc., Bloomington, Minnesota 55437, USA. evanlaar@mgipharma.com
|
|
pubmed:publicationType |
Journal Article
|
